LipoScience NMR LipoProfile Test Sales Force To Reach 90 Reps By 2004
This article was originally published in The Gray Sheet
Executive Summary
LipoScience will continue to ramp up marketing of the NMR LipoProfile test for cardiovascular disease risk assessment with proceeds from a planned initial public offering of up to $100 mil
You may also be interested in...
Financings In Brief
LipoScience IPO: Sale of 5 mil. shares in $80 mil. initial public offering is postponed Sept. 19. The maker of the NMR LipoProfile cardiovascular disease risk assessment test planned on pricing each share at $14-16 (1"The Gray Sheet" March 11, 2002, p. 18). The IPO, which originally had been targeted to raise $100 mil., was delayed following the stock market downturn the week of Sept. 16. The NMR LipoProfile is more expensive than traditional, standard-of-care cholesterol tests, which may have contributed to investor jitters...
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.